Cover Image
市場調查報告書

老年癡呆症及異動症的治療市場:全球市場方案,市場規模,預測,趨勢,及預測

Treatment for Syndromes of Dementia and Movement Disorders Market (By Type: Movement Disorders, Progressive Dementia, and Other; By Geography) Global Scenario, Market Size, Outlook, Trend, and Forecast, 2015-2024

出版商 Variant Market Research LLP 商品編碼 550290
出版日期 內容資訊 英文 99 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老年癡呆症及異動症的治療市場:全球市場方案,市場規模,預測,趨勢,及預測 Treatment for Syndromes of Dementia and Movement Disorders Market (By Type: Movement Disorders, Progressive Dementia, and Other; By Geography) Global Scenario, Market Size, Outlook, Trend, and Forecast, 2015-2024
出版日期: 2017年08月17日 內容資訊: 英文 99 Pages
簡介

本報告提供全球老年癡呆症及異動症的治療市場相關調查,彙整市場概要和各類型,地區別趨勢,及打入市場的主要企業簡介等資料。

第1章 序論

第2章 摘要整理

第3章 市場概要

  • 市場概要,趨勢,預測,觀點
  • 市場佔有率分析:企業競爭模式
  • 價值鏈分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 波特五力分析

第4章 各類型市場:市場規模與預測

  • 概要
  • 異動症
    • 帕金森氏症
    • 進行性
    • 進行性核上麻痺
    • 多系統萎縮症
    • 蛋白球色素退變
    • 其他
  • 漸進性癡呆
    • 阿茲海默症
    • 路易氏體型失智症
    • 額顳葉型失智症
    • 其他
  • 進行性癡呆與神經異常
    • 亨丁頓舞蹈症
    • 大腦皮質基底核神經節變性症
    • 肌肉萎縮性側索硬化症

第5章 各地區市場:市場規模與預測

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他各國

第6章 企業簡介

目錄

Title:
Treatment for Syndromes of Dementia and Movement Disorders Market
(By Type: Movement Disorders, Progressive Dementia, and Progressive Dementia with Neurological Abnormalities; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend, and Forecast, 2015-2024.

Global Treatment for Syndromes of Dementia and Movement Disorders Market is estimated to reach $28.6 Billion by 2024; growing at a CAGR of 8.9% from 2016 to 2024. Dementia is loss of thinking capability or a collection of symptoms caused by disorders affecting brain. Dementia and movement disorders are majorly triggered due to damages caused to brain instigated by diseases or a series of strokes. As stated in World Alzheimer Report 2015, 46 million people have been affected by dementia and the number is anticipated to increase to 131.5 million by 2050. People above the age of 65 years are more likely to be affected by dementia and movement disorders. These disorders progress gradually and gets worse over the time. Diagnosis at early stage is very essential in order to ensure accurate diagnosing and treatment to the person.

Increasing geriatric population, growing prevalence of neurodegenerative disorders, increasing awareness among people, and availability of various healthcare services are the factors boosting the development of the global treatment for syndrome of dementia and movement disorders market. Moreover, various awareness programs and market expansion are likely to provide growth opportunities in the coming years. Nevertheless, long down-time for approval and lack of proper management of these disorders might hamper the development of the market.

The global treatment for syndromes of dementia and movement disorders market is bifurcated into type and geography. By type, the market is sub-segmented into movement disorders (Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, hallervorden-spatz disease and others), progressive dementia (Alzheimer's disease, Lewy body dementia, frontotemporal dementia/pick and others) and progressive dementia with neurological abnormality (corticobasal ganglionic degeneration, Huntington's disease, amyotrophic lateral sclerosis(ALS)).

By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers Germany, Italy, UK, France, Spain, and others. Asia-Pacific covers Japan, China, India, and others. RoW covers South America, Middle East, and Africa.

The key players in the market include Baxter International, Inc., Valeant Pharmaceutical International, Abbott Laboratories, Inc., AstraZeneca GmbH, AG, Merck & Co., Inc., Sanofi S.A., Novartis AS, F. Hoffmann-La Roche, Bristol-Myers Squibb, and Pfizer, Inc., among others.

The key takeaways from the report:

  • The report will provide a detailed analysis of Global Treatment for Syndromes of Dementia and Movement Disorders Market with respect to major segments such as type, and geography
  • The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
  • Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
  • An exhaustive regional analysis of Treatment for Syndromes of Dementia and Movement Disorders Market from 2015 to 2024 has been included in the report
  • Profile of the key players in the Global Treatment for Syndromes of Dementia and Movement Disorders Market will be provided, which include key financials, product & services, new developments and business strategies

Scope of the Global Treatment for Syndromes of Dementia and Movement Disorders Market:

Type Segments

  • Movement Disorders
    • Parkinson's Disease
    • Progressive Supranuclear Palsy
    • Multiple System Atrophy
    • Hallervorden-Spatz Disease
    • Others
  • Progressive Dementia
    • Alzheimer's Disease
    • Lewy Body Dementia
    • Frontotemporal Dementia/Pick
    • Others
  • Progressive Dementia with Neurological Abnormality
    • Corticobasal Ganglionic Degeneration
    • Huntington's Disease
    • Amyotrophic Lateral Sclerosis (ALS)

Geography Segments

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • UK
    • France
    • Spain
    • Other
  • Asia-Pacific
    • Japan
    • China
    • India
    • Others
  • RoW
    • South America
    • Middle East
    • Africa

Table of Contents

Chapter 1: Prefix

  • 1.1. Market Scope
  • 1.2. Report Description
  • 1.3. Research Methodology
    • 1.3.1. Primary Research
    • 1.3.2. Secondary Research
    • 1.3.3. In-house Data Modeling

Chapter 2: Executive Summary

Chapter 3: Market Outline

  • 3.1. Market Inclination, Trend, Outlook and Viewpoint
  • 3.2. Market Share Analysis: Company's Competitive Scenario
  • 3.3. Value Chain Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Impact Analysis
    • 3.4.2. Restraints
      • 3.4.2.1. Impact Analysis
    • 3.4.3. Opportunities
  • 3.5. Porter's five forces analysis
    • 3.5.1. Factors Impact Analysis

Chapter 4: Treatment for Syndromes of Dementia and Movement Disorders Market by Type: Market Size and Forecast, 2015-2024

  • 4.1. Overview
  • 4.2. Movement Disorders
    • 4.2.1. Current Trend and Analysis
    • 4.2.2. Market Size and Forecast
    • 4.2.3. Parkinson's Disease
    • 4.2.4. Progressive Supranuclear Palsy
    • 4.2.4. Multiple System Atrophy
    • 4.2.6. Hallervorden-Spatz Disease
    • 4.2.7. Others
  • 4.3. Progressive Dementia
    • 4.3.1. Current Trend and Analysis
    • 4.3.2. Market Size and Forecast
    • 4.3.3. Alzheimer's Disease
    • 4.3.4. Lewy Body Dementia
    • 4.3.5. Frontotemporal Dementia/Pick
    • 4.3.6. Others
  • 4.4. Progressive Dementia with Neurological Abnormality
    • 4.4.1. Current Trend and Analysis
    • 4.4.2. Market Size and Forecast
    • 4.4.3. Huntington's Disease
    • 4.4.4. Corticobasal Ganglionic Degeneration
    • 4.4.5. Amyotrophic Lateral Sclerosis(ALS)

Chapter 5: Treatment for Syndromes of Dementia and Movement Disorders Market by Geography: Market Size and Forecast, 2015-2024

  • 5.1. Overview
  • 5.2. North America
    • 5.2.1. Current Trend and Analysis
    • 5.2.2. Market Size and Forecast
    • 5.2.3. US
      • 5.2.3.1. Market Size and Forecast
    • 5.2.4. Canada
      • 5.2.4.1. Market Size and Forecast
    • 5.2.5. Mexico
      • 5.2.5.1. Market Size and Forecast
  • 5.3. Europe
    • 5.3.1. Current Trend and Analysis
    • 5.3.2. Market Size and Forecast
    • 5.3.3. UK
      • 5.3.3.1. Market Size and Forecast
    • 5.3.4. Germany
      • 5.3.4.1. Market Size and Forecast
    • 5.3.5. France
      • 5.3.5.1. Market Size and Forecast
    • 5.3.6. Italy
      • 5.3.6.1. Market Size and Forecast
    • 5.3.7. Spain
      • 5.3.7.1. Market Size and Forecast
    • 5.3.8. Others
      • 5.3.8.1. Market Size and Forecast
  • 5.4. Asia-Pacific
    • 5.4.1. Current Trend and Analysis
    • 5.4.2. Market Size and Forecast
    • 5.4.3. Japan
      • 5.4.3.1. Market Size and Forecast
    • 5.4.4. China
      • 5.4.4.1. Market Size and Forecast
    • 5.4.5. India
      • 5.4.5.1. Market Size and Forecast
    • 5.4.6. Others
      • 5.4.6.1. Market Size and Forecast
  • 5.5. RoW
    • 5.5.1. Current Trend and Analysis
    • 5.5.2. Market Size and Forecast
    • 5.5.3. Middle East
      • 5.5.3.1. Market Size and Forecast
    • 5.5.4. South America
      • 5.5.4.1. Market Size and Forecast
    • 5.5.5. Africa
      • 5.5.5.1. Market Size and Forecast

Chapter 6: Company Profiles

  • 6.1. Valeant Pharmaceutical International
  • 6.2. AstraZeneca GmbH
  • 6.3. F. Hoffmann-La Roche, AG
  • 6.4. Abbott Laboratories, Inc.
  • 6.5. Merck & Co., Inc.
  • 6.6. Sanofi S.A.
  • 6.7. Novartis AG
  • 6.8. Bristol-Myers Squibb
  • 6.9. Baxter International, Inc.
  • 6.10. Pfizer, Inc.
Back to Top